A recent study unveiled at the ACR Convergence 2025 suggests that certain medications originally developed for diabetes and weight-loss treatment may also help reduce flare-ups in Rheumatoid Arthritis (RA).
Specifically, the focus is on the drug class known as GLP‑1 receptor agonists (and also some SGLT‑2 inhibitors). Researchers found that among RA patients already on standard treatments (like disease-modifying antirheumatic drugs, or DMARDs), those who were also prescribed these metabolic drugs tended to have fewer disease flares and improved markers of inflammation compared with patients who did not take them, according to the NDTV report.
How these diabetes drugs may influence arthritis symptoms
For example, in one observational study of 173 RA patients with a BMI of around 27, those who took a GLP-1 agonist showed a 32% improvement in disease activity after one year, versus a 17% improvement in a control group. Weight loss on average was about 4.4 kg in the treatment group vs 1.2 kg in the control group. Markers like CRP/ESR and LDL cholesterol also improved.
Why might this happen? The science behind the link
Well, RA isn’t just “joint pain” — it’s an autoimmune disease linked with inflammation, metabolic issues (obesity, insulin resistance), and cardiovascular risk. GLP-1 drugs help with weight loss, better insulin sensitivity and reduced vascular inflammation. The theory is that they might “pull down” overall inflammation and thus help with RA activity.
Experts urge caution: Early signals, not proof
But here’s the important caveat: this research is preliminary. The studies so far are retrospective/observational (not the most rigorous form of trial), sample sizes are modest, and they don’t yet prove causation (i.e., that the drug directly reduces RA flares rather than via improved metabolism).
For people with RA, this doesn’t mean “stop your current therapy and start a GLP-1 drug for RA”. Standard RA therapies (DMARDs, biologics, etc) remain the backbone. Instead, if you have RA and metabolic issues (diabetes, obesity, cardiovascular risk), this might become an additional avenue worth discussing with your rheumatologist.
In short, it’s an exciting intersection of metabolic medicine and rheumatology, hinting at novel therapeutic paths. But it’s not yet ready to change standard RA care. Weight control, managing insulin resistance, reducing cardiovascular risk and keeping inflammation under control—all remain vital. Always consult your doctor.
ALSO READ: Beyond back pain: Why spine health is the foundation of overall wellness
